This study was funded by grants from the National Institutes of Health (P01HL-160487, P30DK127984, UL1TR003163, and AI-158357), The Welch Foundation (I-1793), and the Leducq Foundation (19CVD04)
But of course, since most of the research hasnt been conducted on humans, we need to be cautious about making too much of these findings
GHK-Cu is a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) complexed with a copper 2+ ion
Safety in patients with existing mild-moderate liver disease Correlation between weight loss and estimated liver fat reduction TRIUMPH-2 (Ongoing, Expected 2026) Primary Endpoints: Weight loss in diabetic patients HbA1c reduction Secondary Endpoints (Liver): Liver enzymes Metabolic markers Diabetic Population Note: Higher prevalence of MASLD/NASH (~40-50%), so liver benefits particularly important in this group
Traditionally, obesity management focused on lifestyle modifications, including dietary restrictions and increased physical activity